NICE okays Roche liver cancer immunotherapy, Sanofi’s rare disease drugPreviously-untreated patients with hepatocellular carcinoma (HCC), a common form of liver cancer, will have an immunotherapy-based treatment option Share XNICE okays Roche liver cancer immunotherapy, Sanofi’s rare disease drughttps://pharmaphorum.com/news/nice-okays-roche-liver-cancer-immunotherapy-sanofis-rare-disease-drug/
Merck & Co/Eisai eye kidney cancer use for immunotherapy combinationMerck & Co and Eisai are to file results from a phase 3 trial testing a combination of Share XMerck & Co/Eisai eye kidney cancer use for immunotherapy combinationhttps://pharmaphorum.com/news/merck-co/
Europe approves Roche’s Tecentriq liver cancer combinationThe European Commission has approved Roche’s Tecentriq immunotherapy, in combination with its established cancer drug Avastin, for patients Share XEurope approves Roche’s Tecentriq liver cancer combinationhttps://pharmaphorum.com/news/europe-approves-roches-tecentriq-liver-cancer-combination/
Roche’s Tecentriq/Avastin combo gets liver cancer nodThe FDA has approved Roche’s combination of its Tecentriq and Avastin drugs in previously-untreated hepatocellular carcinoma (HCC) – Share XRoche’s Tecentriq/Avastin combo gets liver cancer nodhttps://pharmaphorum.com/news/roches-tecentriq-avastin-combo-gets-liver-cancer-nod/
AZ nabs a positive study for Imfinzi plus tremelimumab in liver cancerAfter a long run of trial disappointments, AstraZeneca is celebrating a win for its immuno-oncology combination of Imfinzi Share XAZ nabs a positive study for Imfinzi plus tremelimumab in liver cancerhttps://pharmaphorum.com/news/astrazeneca-imfinzi-tremelimumab-liver-cancer-asco-2020/
Roche files Tecentriq, Avastin combo as a liver cancer therapyRoche has filed for approval of a two-drug combination of its Tecentriq and Avastin drugs in previously-untreated hepatocellular Share XRoche files Tecentriq, Avastin combo as a liver cancer therapyhttps://pharmaphorum.com/news/roche-files-tecentriq-avastin-combo-as-a-liver-cancer-therapy/
FDA decision on Opdivo/Yervoy in liver cancer due next MarchThe FDA has started a priority review of Bristol-Myers Squibb’s immuno-oncology combination of Opdivo and Yervoy in liver Share XFDA decision on Opdivo/Yervoy in liver cancer due next Marchhttps://pharmaphorum.com/news/fda-decision-on-opdivo-yervoy-in-liver-cancer-due-next-march/
Sillajen explains Pexa-Vec trial failure – it was the rescue medsSouth Korean biotech Sillajen was hit hard last week when its oncolytic virus therapy Pexa-Vec failed a phase Share XSillajen explains Pexa-Vec trial failure – it was the rescue medshttps://pharmaphorum.com/news/sillajen-explains-pexa-vec-trial-failure-it-was-the-rescue-meds/
BMS has another Opdivo setback after liver cancer trial failureBristol-Myers Squibb’s cancer immunotherapy Opdivo has suffered another setback after it failed to improve on standard care in Share XBMS has another Opdivo setback after liver cancer trial failurehttps://pharmaphorum.com/news/bms-has-another-opdivo-setback-after-liver-cancer-trial-failure/
